Trials / No Longer Available
No Longer AvailableNCT00413270
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
A Canadian Open-label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant CML-blast crisis, CML-accelerated phase or CML-chronic phase when treated with nilotinib. Patients will be provided access to nilotinib until the drug is available on the market.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nilotinib |
Timeline
- Start date
- 2006-12-01
- First posted
- 2006-12-19
- Last updated
- 2011-07-13
Locations
18 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00413270. Inclusion in this directory is not an endorsement.